| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5247 | Trpa1-in-7 | Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain |
|
| DCC5248 | Trpm2 Inhibitor A23 | Novel selective inhibitor of the transient receptor potential melastatin 2 (TRPM2) channel, exhibiting TRPM2 selectivity over TRPM8 and TRPV1 channels as well as phospholipase A2 and showing neuroprotective activity in vitro, and significantly reducing ce |
|
| DCC5249 | Trpm8-agonist-1 | Novel agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel |
|
| DCC5250 | Trpv6 Inhibitor Cis-22a | Novel selective TRPV6 inhibitor |
|
| DCC5251 | Trxr1-in-b19 | Novel TrxR1 inhibitor, selectively killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation |
|
| DCC5252 | Tryptanthrin | Natural DNA gyrase inhibitor, blocking leukotriene production, inhibiting P-glycoprotein, and showing anti-inflammatory and anti cancer activities |
|
| DCC5253 | Tryptorubin A | Natural Polycyclic Peptide from a Fungus-Derived Streptomycete |
|
| DCC5254 | Tshr-nam-s37a | Novel highly selective negative allosteric modulator (NAM) of thyrotropin receptor (TSHR), binding at the ectodomain/TMD interface, between the converging helix, ECL1 and the IA, noncompetitively inhibiting PAM-C2-activation |
|
| DCC5255 | Tslp-in-11a | Novel human thymic stromal lymphopoietin (TSLP) inhibitor |
|
| DCC5256 | Ts-pysa | Novel isoform-selective inhibitor of the tumor-associated hCA IX and XII |
|
| DCC5257 | Tsri265 | Novel αvβ3 ligand, disrupting the integrin-MMP2 interaction and showing antiangiogenic activit, inhibiting angiogenesis and tumor growth in vivo |
|
| DCC5258 | Tta-a8 | Novel antagonist of T-type calcium channels |
|
| DCC5259 | Ttk Protac 8e | First-in-class potent threonine tyrosine kinase (TTK) PROTAC, demonstrating strong TTK degradation in COLO-205 human colorectal cancer cells with DC 50 values of 1.7 nM |
|
| DCC5260 | Ttk Protac 8j | First-in-class potent threonine tyrosine kinase (TTK) PROTAC, demonstrating strong TTK degradation in COLO-205 human colorectal cancer cells with DC 50 values of 3.1 nM |
|
| DCC5261 | Ttr Stabilizer L6 | Novel transthyretin (TTR) stabilizer, binding to the T4 binding pocket of TTR and preventing the dissociation of TTR to monomer |
|
| DCC5262 | Ttt-3002 | FLT3 Kinase Inhibitor, Overcoming Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia |
|
| DCC5263 | Tu-514 | LpxC substrate-analog inhibitor |
|
| DCC5264 | Tubulin-in-3n | Novel inhibitor of tubulin polymerization and caused HepG2 cells arrest in G2/M phase |
|
| DCC5265 | Tubulin-in-iia | Novel potent tubulin polymerization inhibitor, forming stable interactions in the colchicine-binding site of tubulin, showing significant antiproliferative activities on a panel of tumor cell lines |
|
| DCC5266 | Tug-1907 | Novel allosteric modulator of free fatty acid receptor 3 (FFA3, previously GPR41) |
|
| DCC5267 | Tug-2015 | Novel allosteric modulator of free fatty acid receptor 3 (FFA3, previously GPR41) |
|
| DCC5268 | Tulobuterol Hydrochloride | Long-acting beta2-adrenergic receptor agonist |
|
| DCC5269 | tumor Metastasis Blocker 5k | Novel Inhibitor of Metastatic Cancer Cell Migration and Invasion |
|
| DCC5270 | Tunicamycin | Antibiotic, inhibiting the first step in the N-linked glycosylation in eukaryotes and inducing ER stress to activate the unfolded protein response (UPR) |
|
| DCC5271 | Turneroic Acid | Inhibitor of bacterial biofilm formation in Staphylococcus epidermidis |
|
| DCC5272 | Tutuilamide A | Natural potent porcine pancreatic elastase (PPE) inhibitor |
|
| DCC5273 | Txa1 Hydrochloride | Novel anticancer agent, affecting steroid biosynthesis, increasing RagD expression, and causing abnormal cellular cholesterol localization |
|
| DCC5274 | Txa-709 | Novel disruptor of the bacterial protein, FtsZ |
|
| DCC5275 | Ty-51469 | Chymase inhibitor, preventing the development and progression of non-alcoholic steatohepatitis, improving vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats |
|
| DCC5276 | Tyk2 Jh2-in-48 | Novel highly potent and selective TYK2 JH2 inhibitor, providing robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model |
|
